Tumor-Derived Exosomal miR-620 as a Diagnostic Biomarker in Non-Small-Cell Lung Cancer

Figure 2

Exosomal miR-620 was decreased in NSCLC significantly. (a) qRT-PCR assessment of miR-620 expression levels from serum exosomes (EXO) and supernatant depleted exosomes (EDS). (b) Analysis of the expression level of miRNA-620 in RNase A-treated exosomes or serum. (c) qRT-PCR analysis of exosome miR-620 expression after incubation at room temperature. The serum exosomal miR-620 demonstrated a significant relationship with (d) drinking status, (e) T stage, and (f) distant metastasis. Serum exosomal miR-620 expression in NSCLC (G) or early-stage NSCLC patients (h) and healthy donors were evaluated by the qRT-PCR assay (, ,, and ns: not significant).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)